Glaxo hails 'important milestone' for HIV drug
Drugs giant GlaxoSmithKline has reported positive results from an initial study into its development of a drug for HIV treatment.
Drugs giant GlaxoSmithKline has reported positive results from an initial study into its development of a drug for HIV treatment.
ViiV Healthcare, a global HIV firm established by Glaxo and Pfizer, and Shionogi & Co announced this morning that the SPRING-2 (ING113086) - the Phase III study of the investigational integrase inhibitor dolutegravir in treatment-nave adults with HIV-1 - met its primary objective, showing non-inferiority of dolutegravir to raltegravir.
"The SPRING-2 findings indicate that once daily unboosted dolutegravir may offer people living with HIV an additional treatment option in the future," sid ViiV's Chief Medica Officer John Pottage.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"These are the first large-scale safety and efficacy data in nave patients, and we look forward to seeing further data in 2012 to build a more comprehensive picture of the role of dolutegravir," he said.
During a period of 48 weeks, 88% of study participants on the one-daily drug were "virologcially supressed" compared with 85% of participants on raltegravir (twice daily).
Shionogi & Co's Chief Executive Officer, Tsutae Nagata, said that the findings mark an "important milestone" for dolutegravir and the Shionogi-ViiV joint venture.
BC
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Gender pensions gap to take 20 years to fix unless ‘decisive action taken’
Scottish Widows finds that - based on current projections - it will take until 2045 to bridge the gender pensions gap
By Chris Newlands Published
-
Three British small cap bargains to boost profitability
Three British small caps to invest in, according to Edward Wielechowski of the Odyssean Investment Trust
By Ed Wielechowski Published